ArticleMedical oncology (Northwood, London, England)2015

Rituximab and bortezomib (RB): a new effective regimen for refractory or relapsed indolent lymphomas.

Hou Yun et al.PubMed ↗Publisher ↗

No numbers read from the abstract.